Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Income: 2010-2025

Historic Operating Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $44.1 million.

  • Arrowhead Pharmaceuticals' Operating Income rose 127.19% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year increase of 116.36%. This contributed to the annual value of $98.3 million for FY2025, which is 116.36% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Operating Income stood at $44.1 million, which was up 126.64% from -$165.6 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Operating Income peaked at $381.2 million during Q1 2025, and registered a low of -$176.1 million during Q2 2024.
  • Moreover, its 3-year median value for Operating Income was -$126.2 million (2024), whereas its average is -$60.5 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Operating Income tumbled by 362.00% in 2024, and later surged by 402.08% in 2025.
  • Arrowhead Pharmaceuticals' Operating Income (Quarterly) stood at -$63.3 million in 2021, then spiked by 33.46% to -$42.1 million in 2022, then tumbled by 224.07% to -$136.5 million in 2023, then declined by 18.21% to -$161.4 million in 2024, then spiked by 127.19% to $44.1 million in 2025.
  • Its Operating Income stands at $44.1 million for Q3 2025, versus -$165.6 million for Q2 2025 and $381.2 million for Q1 2025.